Medical Disorders
Resources
Basic InformationLookupsLatest News
Coronavirus Strikes Men, Older People the HardestWhistleblower Complaint Filed, California Case Spurs Changes in CDC Coronavirus Testing EffortsImaging Scans May Lead to Shorter TB TreatmentAHA News: What Heart Patients Should Know About CoronavirusHealthy Heart in Your 20s, Healthier Brain Decades LaterScientists Spot Early Markers of Coronavirus in Lungs of PatientsHow to Prepare, Protect Yourself From CoronavirusMore Than 4 in 10 Americans Are Now Obese: CDCTrump Taps Pence to Head Coronavirus Response, As 1st U.S. Case of 'Unknown Origin' SpottedDrug Offers Hope Against Tough-to-Treat Chronic CoughWeight Gain Is No Friend to Aging LungsSugary Sodas Wreak Havoc With Cholesterol Levels, Harming the HeartMore Countries Report Coronavirus Cases, as Outbreak in U.S. Looks CertainU.S. Veterans With Blocked Leg Arteries Seeing Better ResultsBad Sleep, Bad Diet = Bad Heart?Could Heartburn Meds Spur Growth of Drug-Resistant Germs in Your Gut?How Coronavirus Raced Through Quarantined Cruise ShipCoronavirus Outbreak in America Is Coming: CDCGlobal Coronavirus Outbreaks Raise Fears of PandemicGlobal Coronavirus Outbreaks Worry Experts, as U.S. Cases Reach 34Sticking With Meds Lowers Lupus Patients' Diabetes RiskU.S. Coronavirus Cases Reach 34: CDCAHA News: Research Opens New Avenues to Reduce Foot, Toe AmputationsYour Best Bet Against Heart Attack, Stroke? Lower Blood PressureLung Diseases on the Rise WorldwideNew China Coronavirus Cases Decline, 2 Passengers From Affected Cruise Ship DieAHA News: What Women Need to Know About Breast Cancer and Heart DiseaseU.S. Scientists Take Key Step Towards Towards Coronavirus VaccineQuarantine Ends on Cruise Ship in Japan as Coronavirus Cases Near 75,000AHA News: Race and Gender May Tip the Scales on Traditional Stroke Risk FactorsMeasles Complications Can Affect Every Organ: StudyBabies' Exposure to Household Cleaning Products Tied to Later Asthma RiskCoronavirus: Are U.S. Hospitals Prepared?14 Americans From Cruise Ship Hit By Coronavirus Test Positive for InfectionHot Chocolate Could Help Ease Painful Clogged Leg VesselsAntiviral Drug, Plasma Transfusions Show Promise in Treating CoronavirusHow to Dispel Your Child's Fears About the New CoronavirusCholesterol Drugs Might Help Curb 'High-Risk' Prostate CancersCoronavirus Spreads Most Easily When Patients Are Sickest: CDCWill Brushing and Flossing Protect You Against Stroke?Young Black Adults More Prone to Stroke, but Don't Know ItAHA News: Stroke Rates Down for Mexican Americans, Up for White AdultsCoronavirus Cases, Deaths Rise Sharply, While 2 New Cases Reported in U.S.Scientists Spot Antibody That Might Help Diagnose, Treat Autoimmune DisordersCoronavirus in America: Keep Your Panic in CheckCoronavirus Spread Slows, But Death Toll Jumps to 1,113Growing Up in U.S. 'Stroke Belt' Bad for the Brain Later in LifeShingles Vaccine Bonus: Reduced Risk of Stroke?Air Pollution Made in One State Can Cause Deaths in OthersWere You Born in an H1N1 Flu Year or an H3N2? It Matters
Questions and AnswersVideosLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

First Drug Approved for Treatment of Peanut Allergy in Children


HealthDay News
Updated: Feb 3rd 2020

new article illustration

MONDAY, Feb. 3, 2020 (HealthDay News) -- The U.S. Food and Drug Administration approved Palforzia (Peanut [Arachis hypogaea] Allergen Powder-dnfp) to alleviate allergic reactions to accidental peanut exposure, the agency announced late Friday.

Palforzia, a powder manufactured from peanuts, is indicated for initiation in individuals aged 4 to 17 years old with a confirmed peanut allergy. Treatment may be continued in individuals aged 4 years and older. "When used in conjunction with peanut avoidance, Palforzia provides an FDA-approved treatment option to help reduce the risk of these allergic reactions in children with peanut allergy," Peter Marks, M.D., Ph.D., director of the FDA Center for Biologics Evaluation and Research, said in an agency news release.

The FDA notes that Palforzia cannot be used for emergency treatment of allergic reactions. Treatment involves three phases, including initial dose escalation, given on a single day; up-dosing, which involves 11 increasing dose levels over several months; and maintenance. The initial dose escalation and the first dose of each up-dosing level are administered under the supervision of a health care professional. Once patients have completed all up-dosing levels, they can begin the maintenance phase. Palforzia is packaged in pull-apart color-coded capsules for the dose escalation and up-dosing levels and is packaged in a sachet for maintenance treatment. The powder from the capsules or sachet is to be mixed with a small amount of food such as applesauce, yogurt, or pudding for the patient to consume.

Approval was based on data from a randomized, double-blind, placebo-controlled study in about 500 peanut-allergic individuals. In an oral challenge after six months of maintenance treatment, 67.2 percent of individuals who received Palforzia tolerated a 600-mg dose of peanut protein with no more than mild allergic symptoms versus 4 percent of those who received placebo. In two double-blind, placebo-controlled studies of about 700 peanut-allergic individuals, the most commonly reported side effects with Palforzia included abdominal pain, vomiting, nausea, tingling in the mouth, itching in the mouth and ears, cough, runny nose, throat irritation and tightness, hives, wheezing, and shortness of breath and anaphylaxis.

Approval was granted to Aimmune Therapeutics.

More Information




Facebook

Amazon Smile

 

Children and Adult services are available now with no wait time.  

Please contact HBH at 860-548-0101, option 2.

 


powered by centersite dot net